Advaxis (NASDAQ:ADXS) posted its earnings results on Thursday. The biotechnology company reported ($0.02) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.02, MarketWatch Earnings reports.
Shares of ADXS stock traded up $0.13 on Friday, hitting $0.60. The stock had a trading volume of 85,196,846 shares, compared to its average volume of 4,958,332. The firm has a market capitalization of $87.38 million, a P/E ratio of -3.16 and a beta of 2.46. Advaxis has a 1 year low of $0.26 and a 1 year high of $1.57. The company’s 50 day moving average price is $0.45 and its 200-day moving average price is $0.54.
An institutional investor recently raised its position in Advaxis stock. Morgan Stanley increased its stake in shares of Advaxis, Inc. (NASDAQ:ADXS) by 127.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,282 shares of the biotechnology company’s stock after purchasing an additional 60,075 shares during the quarter. Morgan Stanley owned 0.07% of Advaxis worth $50,000 at the end of the most recent quarter. 6.85% of the stock is owned by institutional investors.
Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.
Further Reading: What strategies should day traders use to execute a trade?
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.